Welcome to our dedicated page for Spyre Therapeutics news (Ticker: SYRE), a resource for investors and traders seeking the latest updates and insights on Spyre Therapeutics stock.
Spyre Therapeutics (NASDAQ: SYRE) is a clinical-stage biotechnology company pioneering novel therapies for inflammatory bowel disease through advanced antibody engineering and precision medicine approaches. This dedicated news hub provides investors and industry professionals with timely updates on SYRE's scientific advancements, clinical developments, and strategic initiatives.
Access comprehensive coverage of Spyre's progress in developing extended half-life monoclonal antibodies targeting key IBD pathways, including α4β7 integrin and cytokine pathways. The resource consolidates official press releases, clinical trial milestones, and regulatory updates to help stakeholders track the company's innovative pipeline.
Key focus areas include updates on SYRE's lead candidates, partnership announcements with research institutions, and progress in rational combination therapy development. Users will find verified information about the company's precision medicine platform and its applications in ulcerative colitis and Crohn's disease treatment strategies.
Bookmark this page for direct access to Spyre Therapeutics' latest developments in biopharmaceutical innovation. Check regularly for updates on clinical trial phases, scientific publications, and strategic collaborations shaping the future of IBD treatment.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on antibody engineering for IBD and immune-mediated diseases treatment, has announced new equity inducement awards. The company's independent Compensation Committee approved stock options to purchase 93,200 shares for five non-executive employees under their 2018 Equity Inducement Plan.
The stock options were granted on April 1, 2025, with a 10-year term and an exercise price of $15.295 per share, matching Spyre's closing price on that date. The vesting schedule includes 25% after the first year of employment, followed by monthly vesting of 1/48th of the shares, contingent on continued service with the company.
Spyre Therapeutics (NASDAQ: SYRE) has initiated dosing in a Phase 1 clinical trial of SPY003, its half-life extended anti-IL-23 monoclonal antibody, marking their fourth on-time clinical trial initiation in nine months. The trial (NCT06873724) is a double-blind, placebo-controlled single-ascending dose study expected to enroll approximately 56 healthy adult volunteers.
Preclinical data shows SPY003 is highly potent with potential for quarterly or biannual dosing, suggesting improved efficacy and convenience over first-generation anti-IL-23 antibodies. The study's primary endpoint is safety, with pharmacokinetics as a secondary endpoint.
Interim pharmacokinetic and safety data are anticipated in the second half of 2025. Following interim results, Spyre plans to incorporate SPY003 into its Phase 2 platform trial in ulcerative colitis, which will evaluate three investigational monotherapies and three investigational combination therapies.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on antibody engineering for IBD and immune-mediated diseases treatment, has announced new inducement awards. The company's independent Compensation Committee approved stock options to purchase 132,200 shares for five non-executive employees under their 2018 Equity Inducement Plan.
The options were granted on March 3, 2025, with a 10-year term and an exercise price of $19.49 per share, matching Spyre's closing price on that date. The vesting schedule includes 25% after one year of employment, followed by monthly vesting of 1/48th of shares, contingent on continued service with Spyre.
Spyre Therapeutics (NASDAQ:SYRE) reported Q4 and full year 2024 results, highlighting positive interim data from its Phase 1 trial of SPY001. The company strengthened its position with a $230 million public offering and maintains $603.1 million in cash reserves, extending runway into H2 2028.
Key developments include planned Phase 2 platform trial initiation in ulcerative colitis by mid-2025, expansion into rheumatoid arthritis with SPY002, and multiple expected data readouts. Q4 2024 financial results showed R&D expenses of $50.5 million (up from $33.7M in Q4 2023), G&A expenses of $10.8 million (down from $14.1M), and a net loss of $56.3 million.
The company's pipeline focuses on three validated targets in IBD treatment, with potential for subcutaneous maintenance dosing as monotherapy or combinations. Interim results for SPY001 showed favorable safety profiles and extended half-life supporting potential Q6M maintenance dosing.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotechnology company focused on antibody engineering and therapeutic combinations for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases, has announced its participation in two upcoming investor conferences in March 2025.
The company will attend the TD Cowen 45th Annual Healthcare Conference in Boston on March 4, 2025, where management will participate in a fireside chat at 3:10pm ET and hold one-on-one meetings. Additionally, Spyre will be present at the Jefferies Biotech on the Beach Summit in Miami on March 11, 2025, for one-on-one meetings.
Live audio webcasts and replays of the TD Cowen fireside chat will be available on the company's investor events website at https://ir.spyre.com/events-and-presentations.
Spyre Therapeutics (NASDAQ: SYRE) presented preclinical findings at the 20th Congress of the European Crohn's and Colitis Organisation (ECCO) demonstrating superior results from combined inhibition of α4β7 integrin and TL1A cytokine compared to individual treatments in mouse colitis models.
The research showed that the company's SPY120 program achieved additive or greater than additive efficacy through combined target inhibition. Pharmacokinetic studies in non-human primates revealed that SPY001 and SPY002 antibodies maintained similar profiles whether administered alone or in combination, suggesting potential for quarterly or twice-annual dosing in humans.
The company plans to initiate a Phase 2 trial in ulcerative colitis patients by mid-2025, testing three combinations: SPY120, SPY130, and SPY230.
Spyre Therapeutics (NASDAQ: SYRE) has announced the approval of inducement stock options for three non-executive employees by its independent Compensation Committee. The grants include options to purchase 35,000 shares of common stock under the company's 2018 Equity Inducement Plan.
The stock options were approved on February 3, 2025, with a 10-year term and an exercise price of $22.65, matching Spyre's closing share price on that date. The vesting schedule includes 25% of shares vesting on the first employment anniversary, followed by monthly vesting of 1/48th of shares thereafter, contingent on continuous service with the company.
Spyre Therapeutics (NASDAQ: SYRE) outlined its 2025 priorities, focusing on its robust clinical pipeline and financial stability. Key highlights include:
Clinical Developments:
- Phase 1 interim results for SPY002 and SPY003 expected in 2Q2025 and 2H2025, respectively.
- Phase 2 platform trial in ulcerative colitis (UC) to start mid-2025, with initial results in 2026.
- Expansion into rheumatoid arthritis (RA) with SPY002; Phase 2 trial initiation in mid-2025 and results in 2026.
Financial Position:
- Preliminary cash and equivalents balance of over $600M as of December 31, 2024, providing runway into 2H2028.
CEO Cameron Turtle emphasized the company's progress in 2024, including first-in-human studies for SPY001 and SPY002 with promising interim results. The company plans to conduct a groundbreaking Phase 2 platform study in UC, testing monotherapies and combination therapies under a single protocol. SPY002's expansion into RA is supported by pre-clinical evidence, showcasing its potential as a first-in-class treatment. Spyre aims to deliver four clinical proof-of-concept readouts in 2026.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on IBD treatments, has announced the approval of inducement stock options by its independent Compensation Committee. The grant includes options to purchase 21,000 shares of common stock awarded to one non-executive employee under the company's 2018 Equity Inducement Plan.
The stock options come with a 10-year term and an exercise price of $24.35, matching Spyre's closing share price on January 2, 2025. The vesting schedule includes 25% after the first year of employment, followed by monthly vesting of 1/48th of the shares, contingent on continuous service with the company.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on Inflammatory Bowel Disease (IBD) treatment, has announced its addition to the Nasdaq Biotechnology Index (NBI), effective December 23, 2024. The inclusion comes as part of the NBI's annual evaluation process. Companies must meet specific eligibility criteria including minimum market capitalization, average daily trading volume, and public company seasoning requirements. The NBI tracks performance of biotechnology and pharmaceutical securities listed on Nasdaq and operates under a modified capitalization-weighted methodology.